Last week, Dr. Gail Naughton, CEO of Histrogen, Inc. a regenerative medicine company that develops solutions based on the products of newborn fibroblasts grown under embryonic conditions, addressed attendees at the 4th Annual Stem Cell Summit in New York. Dr. Naughton presented preliminary mid-trial results from Histrogen’s first human clinical evaluation of it’s promising breakthrough hair loss product ReGenica™
Histrogen’s clinical trial was primarily designed to assess the safety of its product over a five-month period by using a placebo-controlled, randomized study. Its second objective was to examine ReGenica’s efficiency.
At the 12-week scheduled evaluation point, the company was pleased to announce that they not only found no adverse reactions of ReGenica but also that they could honestly say that they were able to see more hair, thicker hair shafts, and what appeared to be the growth of completely new hair follicles on a siggnificant percentage of the test subjects who were treated with ReGenica.
ReGenica is a liquid formula that is the first naturally stabilized and bioactive formulation of wnt proteins and natural cofactors, which are thought to act in the formation of new hair follicles. The trial is currently ongoing, and Histogen expects to release full results from this first clinical study in the first half of 2009.
Read Article
